E. D. Bateman (Cape Town, South Africa), T. Welte (Hanover, Germany)
Do symptomatic asthmatic smokers need a higher maintenance dose when treated with budesonide/formoterol maintenance and reliever therapy than non-smokers?
O. C. P. van Schayck, M. Aubier, R. Buhl, J. Ostinelli, T. Ekström, L. Jörgensen, J. Haughney (Netherlands; Paris, Rueil-Malmaison, France; , Germany; Södertälje, Sweden; Aberdeen, United Kingdom)
|  |
Cessation of combination therapy for asthma during pregnancy
S. Schokker, J. S. Vroegop, R. Aalbers, L. H. Steenhuis, S. H. Wills, A. J. van Loon, T. van der Molen (Groningen, Netherlands)
|  |
Changes in asthma medication use during pregnancy in The Netherlands
S. Schokker, J. S. Vroegop, L. H. Steenhuis, S. H. Wills, A. J. van Loon, T. van der Molen, R. Aalbers (Groningen, Netherlands)
| |
Analyze of pregnancy duration in formoterol/budesonid treated asthmatic pregnants
O. Lavrova, M. Petrova (Saint-Petersburg, Russian Federation)
| |
Improving morning activities in COPD patients with budesonide/formoterol: Assessment of data from two randomised trials using minimal important differences from a morning activities questionnaire
T. Welte, M. Miravitlles, N. Karlsson, S. Peterson, G. S. Eriksson, R. Kessler, P. Hernandez, M. R. Partridge (Germany; Barcelona, Spain; Mölndal, Lund, Sweden; Strasbourg, France; Halifax, Canada; London, United Kingdom)
| |
Efficacy and safety of combined mometasone furoate/formoterol 100/10μg twice daily in subjects with asthma inadequately controlled on low-dose inhaled corticosteroids
E. Meltzer, H. Nolte, C. LaForce (San Diego, Kenilworth, Raleigh, United States Of America)
| |
Reduction in air trapping and dyspnea with an extrafine combination of beclomethasone and formoterol in COPD
P. Tzani, E. Crisafulli, G. Nicolini, E. Clini, M. Aiello, A. Chetta, D. Olivieri (Parma, Pavullo, Italy)
| |
Fluticasone propionate/formoterol fumarate combination therapy is as effective as fluticasone propionate/salmeterol xinafoate, but has a more rapid onset of action in the treatment of asthma
A. Bodzenta-Lukaszyk, A. Dymek, H. Mansikka (Bialystok, Strzelce Opolskie, Poland; Cambridge, United Kingdom)
| |
Does combination therapy lead to better adherence in asthma?
K. Perrin, M. Wijesinghe, M. Williams, M. Weatherall, R. Beasley (Wellington, New Zealand)
| |
Fluticasone propionate/formoterol fumarate combination therapy has an efficacy and safety profile similar to that of its individual components administered concurrently in the treatment of asthma
A. Bodzenta-Lukaszyk, G. Pulka, A. Dymek, H. Mansikka (Bialystok, Cracow, Strzelce Opolskie, Poland; Cambridge, United Kingdom)
| |
Fluticasone propionate/formoterol fumarate combination therapy is more effective than fluticasone propionate alone in the treatment of asthma
D. Bumbacea, G. Pulka, A. Dymek, H. Mansikka (Bucharest, Romania; Cracow, Strzelce Opolskie, Poland; Cambridge, United Kingdom)
| |
Asthma control using a combination of mometasone furoate/formoterol: Grouped analysis of three clinical trials
M. White, H. Nolte, E. Meltzer, R. Nathan (Wheaton, Kenilworth, San Diego, Colorado Springs, United States Of America)
| |
The effects of mometasone furoate/formoterol treatment on quality of life: An analysis of multi-trial AQLQ findings
K. Murphy, E. Meltzer, H. Nolte, R. Nathan (Omaha, San Diego, Kenilworth, Colorado Springs, United States Of America)
| |
Long-term safety of medium- and high-dose mometasone furoate/formoterol combination in persistent asthmatics: Analysis of adverse event incidence, plasma cortisol, and ocular changes
J. Maspero, H. Nolte, I. Cherrez (Buenos Aires, Argentina; Kenilworth, United States Of America; Guayaquil, Ecuador)
| |
Budesonide/formoterol maintenance and reliever therapy use in elderly asthma patients
J. Haughney, O. C. P. van Schayck, M. Aubier, J. Ostinelli, T. Ekström, L. Jörgensen, R. Buhl (Aberdeen, United Kingdom; , Netherlands; Paris, Rueil-Malmaison, France; Södertälje, Sweden; , Germany)
| |
Effect of treatment with mometasone furoate/formoterol combination on rescue medication use
C. LaForce, E. Meltzer, R. Nathan, A. Nayak, H. Nolte, D. Pearlman (Raleigh, San Diego, Colorado Springs, Normal, Kenilworth, Denver, United States Of America)
| |
Comparative evaluation of formoterol budesonide combination MDI and salbutamol MDI for reversibility testing in patients with obstructive airways disease
N. Abhyankar (Pune, India)
| |
Overall asthma control with budesonide/formoterol maintenance and reliever therapy in patients stratified by GINA treatment step
E. D. Bateman, T. W. Harrison, S. Quirce, O. Östlund, M. R. Sears, G. S. Eriksson (Cape Town, South Africa; , United Kingdom; Madrid, Spain; Lund, Sweden; Hamilton, Canada)
| |
The bronchodilatory effect of NVA237 inhaled once daily in patients with COPD
C. Fogarty, D. Banerji, H. Hattersley, L. Di Scala, A. Drollmann (SC, NJ, United States Of America; West Sussex, United Kingdom; Basel, Switzerland)
| |
Efficacy and safety of single doses of inhaled LAS100977 in patients with mild to moderate asthma
J. Beier, R. Fuhr, E. Massana, E. Jiménez, B. Seoane, G. de Miquel, S. Ruiz (Wiesbaden, Berlin, Germany; Barcelona, Spain)
| |